Who is Dr. Jin-Xiong She? Background and Achievements

Dr. Jin-Xiong She ranks among genomic medicine’s most distinguished researchers. His scientific work has changed the way we think about diabetes, aging, and cellular health.

From his early research into autoimmune diseases to founding a precision medicine company, his career spans over three decades. He has published more than 400 scientific papers and secured over $100 million in research funding.

Today, he leads the charge in personalized longevity research through his company Jinfiniti Precision Medicine.

Early Life and Scientific Foundation

A strong family focus on schooling and scientific reasoning set Dr. She on his course in biomedical research. This setting nurtured an initial curiosity in biology and genetics, fostering the sort of incisive thought that would define his research efforts.

His academic pursuits led him across continents, exposing him to various outlooks that later informed his research techniques. He finished his undergraduate degree in China, subsequently earning advanced degrees in France.

He obtained his Master of Science from the National School of Agriculture in 1984. Three years later, in 1987, he was awarded his PhD in Molecular Genetics by the University of Montpellier.

This international foundation gave him a special advantage. He came to integrate Eastern philosophical tenets with the precision of Western scientific rigor.

Academic Career at University of Florida

After completing his doctorate, Dr. She moved to the United States for postdoctoral training. He focused on immunogenetics at the University of Florida, studying the genetic basis of autoimmune disorders.

His rise through the academic ranks was remarkably fast. He advanced from Assistant Professor to Associate Professor, then to Full and Endowed Professor in record time.

This rapid progression reflected his immediate impact on the field. His research productivity and new ideas set him apart from his peers early in his career.

Leadership in Diabetes Research

Dr. She took on major leadership roles at the University of Florida. He served as Division Chief of Experimental Pathology and Director of Research at the university’s Diabetes Center.

These positions placed him at the center of diabetes research. He guided the scientific strategy of a leading center dedicated to understanding this complex disease.

Building Genomic Medicine at Augusta University

In 2002, Dr. She received a prestigious appointment as Georgia Research Alliance Eminent Scholar in Genomic Medicine at Augusta University. This position represented a major investment by the state of Georgia to build world-class research programs.

The appointment came with substantial resources and a clear mandate. He was tasked with establishing a center of excellence in genomic medicine from the ground up.

Founding the Center for Biotechnology and Genomic Medicine

As founding director, Dr. She established the Center for Biotechnology and Genomic Medicine (CBGM) at Augusta University. The center became one of the world’s first academic programs dedicated specifically to genomic medicine.

The CBGM’s mission was ambitious and forward-looking. It aimed to advance “predictive, preventive, personalized and participatory medicine” through interdisciplinary research.

This “4P” philosophy became the guiding principle of his work. It provides a direct connection between his academic research and his later business ventures.

Under his leadership, the center attracted four internationally renowned diabetes research programs. These included major studies like TEDDY (The Environmental Determinants of Diabetes in the Young) and PANDA (Prospective Assessment in Newborns of Diabetes Autoimmunity).

The TEDDY Study and Breakthrough Discoveries

Dr. She played a key role in conceiving and launching the landmark TEDDY study in 2003. This massive international project aimed to identify environmental triggers that cause Type 1 diabetes in genetically susceptible children.

The study’s scale was unprecedented. It screened over 424,000 newborns and enrolled nearly 9,000 high-risk children to follow for 15 years.

Landmark Findings About Diabetes

The TEDDY study produced major discoveries under Dr. She’s leadership. The research revealed that Type 1 diabetes is not a single disease but multiple distinct subtypes with different genetic triggers.

His team identified the first clear genetic evidence for diabetes “endotypes.” Children who develop insulin autoantibodies first have different genetic risk factors than those who develop glutamic acid decarboxylase autoantibodies first.

The research also uncovered important environmental factors. The study found that probiotic exposure during infancy decreased diabetes risk, while certain infant formulas increased it.

His work identified several new genetic regions that influence different stages of disease development. These discoveries moved the field beyond simple genetic models to understand diabetes as a complex, multi-stage process.

Jin-Xiong She and the Transition to Longevity

Dr. She’s transition from diabetes research to aging science was both logical and smart. The biological mechanisms underlying Type 1 diabetes—inflammation, metabolic dysfunction, and cellular damage—are central to the aging process itself.

His skills in developing high-throughput testing technologies transferred directly to wellness and healthspan improvement. The same biomarker discovery methods used in disease research could identify aging-related changes before symptoms appeared.

His research into cellular energy and repair mechanisms earned him recognition as the “King of NAD” in wellness circles.

Founder of Jinfiniti Precision Medicine

In 2018, Dr. She founded Jinfiniti Precision Medicine, where he serves as CEO and Chief Scientific Officer. The company represents the direct application of his “4P medicine” philosophy to consumer health.

Jinfiniti Precision Medicine operates on a scientist-led, data-driven approach. The company provides end-to-end solutions for healthy longevity by optimizing healthspan, performance, and lifespan.

Jinfiniti offers proprietary tests for key aging biomarkers including intracellular NAD+ levels, oxidative stress markers, and senescent cell burden. The company then provides targeted supplements like NAD boosters to address deficiencies found through testing.

This approach represents the personalized medicine principles he developed in academia. Jinfiniti targets diverse markets including clinicians, pharmaceutical companies, and the growing community of longevity enthusiasts and biohackers.

NAD Research and Cellular Health

Dr. She’s current work focuses heavily on NAD (Nicotinamide Adenine Dinucleotide) and its role in cellular function. NAD is a molecule involved in over 500 cellular activities and declines significantly with age.

His research has shown that NAD levels vary dramatically between individuals. The same supplement dose could be optimal for one person but ineffective or harmful for another.

This discovery led to developing the first commercially available intracellular NAD+ test. The test allows individuals to measure their baseline levels and monitor improvement through supplementation.

Scientific Impact and Recognition

Dr. She’s academic record places him among the top biomedical researchers globally. His 400+ peer-reviewed papers have been cited more than 20,000 times, with an H-index ranging from 71 to 79.

His ability to secure large research funding shows the scientific community’s confidence in his work. The $100+ million in competitive grants he has received primarily came from the National Institutes of Health.

His leadership roles included serving as President of the American Diabetes Association’s Council on Immunology, Transplantation, and Immunogenetics, and leading the Chinese Geneticists in America organization.

Beyond metrics, his impact has been life-changing. He shifted the diabetes field from simple genetic models to understanding complex, multi-stage disease processes.

Current Work and Future Directions

Today, Dr. She focuses on a mission close to his heart: helping people extend their healthspan through Jinfiniti’s TAO philosophy. TAO stands for Test, Act, and Optimize—a method that reflects both ancient wisdom and modern science.

His work addresses a critical health challenge facing society. Most people experience a 20-year gap between their healthspan and lifespan—living healthy until about age 60 but surviving until 80 with declining quality of life.

Jinfiniti’s approach aims to close this gap through data-driven interventions. Rather than simply adding years to life, Dr. She’s mission centers on adding life to years.

The company’s philosophy goes beyond typical wellness approaches. It combines rigorous testing with personalized interventions to help individuals maintain vitality, energy, and cognitive function as they age.

His scientific background brings credibility to longevity interventions in a field often lacking solid evidence. This evidence-based approach helps people make informed decisions about their health optimization journey.

A Legacy of Scientific Innovation

Dr. Jin-Xiong She’s career represents the modern scientist-entrepreneur model. He has successfully translated decades of basic research into practical tools for improving human health.

His work has progressed from understanding a devastating autoimmune disease to tackling the fundamental biology of aging itself. Both endeavors share a focus on unraveling biological complexity and converting insights into actionable strategies.

His legacy will be measured not only by his foundational discoveries in diabetes genetics but also by his pioneering efforts in personalized longevity medicine. Through Jinfiniti, he continues working to extend the healthy, vibrant years of human life.